StreetAlpha
Nektar Therapeutics · SEC Form 4

NKTR Insider Trading

From SEC Form 435 trades in 2 yearsUpdated Nov 19, 2026

Every open market buy and sale of Nektar Therapeutics stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $2.5M sold.

← NKTR stock page

Insiders are only selling
Bought, 12 months$00 buys · 0 insiders
Sold, 12 months$2.5M15 sales · 3 insiders
Net−$2.5Mbought minus sold
Planned sales85%of sold value, 10b5-1 plans

Buying and selling by month

open market, last 12 months
Dec2026-01: sold $138KJan2026-02: sold $44KFebMarApr2026-05: sold $42KMay2026-06: sold $1.9MJunJul2026-08: sold $43KAugSepOct2026-11: sold $22KNov
Bought (up)Sold (down)
AI Pro · insider alerts

Get an alert when NKTR insiders trade

We read every Form 4 the moment the SEC posts it and tell you when an NKTR officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.

Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.

Every NKTR insider trade

2 years · newest first
InsiderTypePriceHeld afterFiled
Nov 17, 2026Jonathan ZalevskyChief R&D OfficerSale192$35.85$7K9,378Nov 19Form 4
Nov 17, 2026Howard W RobinPresident & CEOSale429$35.85$15K54,198Nov 19Form 4
Aug 18, 2026Howard W RobinPresident & CEOSale418$71.98$30K54,627Aug 20Form 4
Aug 18, 2026Jonathan ZalevskyChief R&D OfficerSale186$71.98$13K9,570Aug 20Form 4
Jun 30, 2026Jonathan ZalevskyChief R&D OfficerSale plan5,681$70.00$398K9,756Jul 2Form 4
Jun 17, 2026Howard W RobinPresident & CEOSale plan20,000$60.75$1.2M55,045Jun 18Form 4
Jun 15, 2026Jonathan ZalevskyChief R&D OfficerSale plan5,538$60.71$336K15,437Jun 17Form 4
May 19, 2026Howard W RobinPresident & CEOSale444$65.51$29K75,045May 21Form 4
May 19, 2026Jonathan ZalevskyChief R&D OfficerSale199$65.51$13K20,975May 21Form 4
Feb 18, 2026Howard W RobinPresident & CEOSale423$73.00$31K75,489Feb 20Form 4
Feb 18, 2026Jonathan ZalevskyChief R&D OfficerSale180$73.00$13K21,174Feb 20Form 4
Jan 20, 2026Jonathan ZalevskyChief R&D OfficerSale plan3,867$35.67$138K21,354Jan 22Form 4
Nov 25, 2025Howard W RobinPresident & CEOSale2,207$54.28$120K54,245Nov 25Form 4
Nov 25, 2025Mark Andrew WilsonChief Legal OfficerSale630$54.28$34K21,585Nov 25Form 4
Nov 25, 2025Jonathan ZalevskyChief R&D OfficerSale1,157$54.28$63K18,971Nov 25Form 4
🔒 20 more trades. Create a free account or sign in to see them all.

NKTR insider trading FAQ

Are NKTR insiders buying or selling?

Insiders are only selling over the last 12 months. 0 insiders bought $0 of NKTR on the open market in 0 trades, and 3 sold $2.5M in 15 trades, 85% of that under pre-arranged trading plans.

When did an NKTR insider last buy shares?

There has been no open market insider purchase of NKTR in the last two years.

When did an NKTR insider last sell shares?

Jonathan Zalevsky (Chief R&D Officer) sold 192 shares for $7K on Nov 17, 2026.

What is a Form 4?

Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.

Why do insider sales matter less than buys?

Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.

From SEC Form 4 filings · Not investment advice